CS Medica (NGM:CSMED) - Stock Price, News & Analysis

CSMED Stock Overview

CS MEDICA A/S develops, manufactures, and commercializes over the counter medical products containing cannabinoids for the treatment of psoriasis and arthritis. More details

CSMED fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Rewards

Revenue is forecast to grow 46.89% per year

Risk Analysis

Has less than 1 year of cash runway

Makes less than USD$1m in revenue (DKK5M)

Highly volatile share price over the past 3 months compared to the Swedish market

Does not have a meaningful market cap (DKK53M)

+ 2 more risks

CS Medica A/S Competitors

PEPTONIC medical

NGM:PMED

SEK 92.1m

Corline Biomedical

OM:CLBIO

SEK 138.0m

AcuCort

NGM:ACUC

SEK 99.9m

Double Bond Pharmaceutical International

NGM:DBP B

SEK 45.4m

Price History & Performance

Summary of all time highs, changes and price drops for CS Medica
Historical stock prices
Current Share Price	DKK 5.93
52 Week High	DKK 17.99
52 Week Low	DKK 3.05
Beta	-0.72
11 Month Change	-25.64%
3 Month Change	-55.11%
1 Year Change	20.06%
33 Year Change	-38.46%
5 Year Change	n/a
Change since IPO	-44.37%

Recent updates

CS Medica (NGM:CSMED) Is Making Moderate Use Of Debt

Jun 04

Shareholder Returns

	CSMED	SE Pharmaceuticals	SE Market
7D	-2.1%	0.9%	-0.2%
1Y	20.1%	9.3%	11.8%

Return vs Industry: CSMED exceeded the Swedish Pharmaceuticals industry which returned 9.1% over the past year.

Return vs Market: CSMED exceeded the Swedish Market which returned 10.9% over the past year.

Price Volatility

Is CSMED's price volatile compared to industry and market?
CSMED volatility
CSMED Average Weekly Movement	12.6%
Pharmaceuticals Industry Average Movement	10.7%
Market Average Movement	5.5%
10% most volatile stocks in SE Market	11.3%
10% least volatile stocks in SE Market	3.3%

Stable Share Price: CSMED's share price has been volatile over the past 3 months compared to the Swedish market.

Volatility Over Time: CSMED's weekly volatility has decreased from 21% to 13% over the past year, but is still higher than 75% of Swedish stocks.

About the Company

Founded	Employees	CEO	Website
2011	9	Lone Henriksen	www.cs-medica.com

CS MEDICA A/S develops, manufactures, and commercializes over the counter medical products containing cannabinoids for the treatment of psoriasis and arthritis. It offers gels for psoriasis, arthritis, protective nasal, and wound healing; and CBD anti-hair loss serum, as well as sleep nasal sprays and pain patches. The company primarily offers its products under the CANNASEN brand name.

CS Medica A/S Fundamentals Summary

How do CS Medica's earnings and revenue compare to its market cap?
CSMED fundamental statistics
Market cap	DKK 52.60m
Earnings (TTM)	-DKK 12.31m
Revenue (TTM)	DKK 4.67m

17.5x

P/S Ratio

-6.6x

P/E Ratio

Is CSMED overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CSMED income statement (TTM)
Revenue	DKK 4.67m
Cost of Revenue	DKK 2.85m
Gross Profit	DKK 1.81m
Other Expenses	DKK 14.12m
Earnings	-DKK 12.31m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Nov 30, 2024

Earnings per share (EPS)	-0.89
Gross Margin	38.81%
Net Profit Margin	-263.84%
Debt/Equity Ratio	676.5%

How did CSMED perform over the long term?

See historical performance and comparison

CSMED Stock Overview

Rewards

Risk Analysis

CS Medica A/S Competitors

NGM:PMED

SEK 92.1m

OM:CLBIO

SEK 138.0m

NGM:ACUC

SEK 99.9m

NGM:DBP B

SEK 45.4m

Price History & Performance

Recent News & Updates

New major risk - Revenue and earnings growth

New minor risk - Shareholder dilution

New major risk - Market cap size

CS Medica A/S Announces Approval of CANNASEN Pain Patch in Malaysia and Trademark Registration in Thailand

Third quarter 2024 earnings released

CS MEDIC Receives "Intention to Grant" for European Patent Application Concerning Cannasen® Psoriasis Gel, Reinforcing Leadership in Cbd-Infused Dermatological Innovations

Recent updates

New major risk - Revenue and earnings growth

New minor risk - Shareholder dilution

New major risk - Market cap size

CS Medica A/S Announces Approval of CANNASEN Pain Patch in Malaysia and Trademark Registration in Thailand

Third quarter 2024 earnings released

CS MEDIC Receives "Intention to Grant" for European Patent Application Concerning Cannasen® Psoriasis Gel, Reinforcing Leadership in Cbd-Infused Dermatological Innovations

CS Medica A/S to Report Q3, 2024 Results on Jul 31, 2024

CS Medica (NGM:CSMED) Is Making Moderate Use Of Debt

Second quarter 2024 earnings released

CS Medica A/S to Report Fiscal Year 2024 Results on Nov 28, 2024

CS Medica A/S Breaks Through Asian Market Barrier with Approval of Protective Nasal Gel in Malaysia

CS Medica A/S to Report 3 Months Period Ending Dec 31, 2023 Results on Mar 29, 2024

Full year 2023 earnings released: kr.1.18 loss per share (vs kr.0.93 loss in FY 2022)

CS Medica A/S to Report 3 Months 2023 Final Results on Apr 24, 2024

CS Medica A/S Announces FDA Authorization for Commercialization for Eight Products in the U.S. Market

Full year 2023 earnings released: kr.1.18 loss per share (vs kr.0.93 loss in FY 2022)

CS Medica A/S to Report Q4, 2024 Results on Nov 14, 2024

Cs Medica A/S Announces Indian State's Fda Approval for Two Cosmetic Products

New major risk - Share price stability

New major risk - Market cap size

CS Medica A/S to Report Q3, 2023 Results on Aug 08, 2023

CS Medica A/S to Report Q3, 2023 Results on Jul 18, 2023

CS Medica A/S Secures Future Compliance with New Medical Device Regulation Through Signed Contract with Notify Body

New major risk - Market cap size

CS Medica A/S Announces Positive Results from Clinical Trial of Nasal Protect Gel for Hay Fever/Allergic Rhinitis

CS Medica A/S to Report Fiscal Year 2022 Final Results on Jan 27, 2023

CS Medica A/S to Report Q1, 2023 Results on Feb 17, 2023

CS Medica A/S, Annual General Meeting, Feb 09, 2023

CS Medica A/S Provides Update on Clinical Trials

Full year 2022 earnings released: kr.0.90 loss per share (vs kr.0.059 profit in FY 2021)

No independent directors

CS Medica A/S and CanNordic A/S Announce the Resignation of Bo Unéus as Board Member

CS Medica A/S Provides Revenue Guidance for the Year 2022

CS MEDICA Provides Patent Update

CS Medica A/S to Report Fiscal Year 2022 Results on Nov 18, 2022

CS MEDICA A/S Reports Proof of Concept in the Results from the Clinical Trial on NGP-01 (Cannasen®Cbd Psoriasis Gel) Against Placebo

CS MEDICA A/S Announces Groundbreaking Discovery in the Natural Cannabinoid CBD's Activity in the Body

Cs Medica Announces Positive Clinical Trial Results from the Final Report on Nga-01 Gel & Nsa-01 Capsule in Combination Against Placebo

CS Medica A/S Reports the Results from the Clinical Trial on NGA-01(CANNASEN®CBD Arthritis Gel) Against Placebo

CS MEDICA A/S Provides Revenue Guidance for 2023/2024

No independent directors

CS Medica Receives the Final Approval from Hong Kong Customs, the Drug Registration Office

CS MEDICA A/S Provides Patent Update

CS MEDICA A/S Finalizes THC Test At PPB Level on Their Cannasen®Cbd Products to Comply with the Strict Regulations on the Asian Market

CS MEDICA A/S Appoints Heidi Ahlefeldt-Laurvig as Chief Growth Officer and Chief Marketing Officer, Effective May 1, 2022

First quarter 2022 earnings: Revenues and EPS in line with analyst expectations

CS MEDICA A/S Reaffirms Revenue Guidance for the Fiscal Year 2022

CS MEDICA A/S Announces Their CANNANSEN®CBD Anti-Hair Loss Serum Approves in the United Arab Emirates

CS MEDICA A/S Announces an Additional Five Intellectual Property Rights Registrations

No independent directors

Shareholder Returns

Price Volatility

About the Company

CS Medica A/S Fundamentals Summary

17.5x

-6.6x

Earnings & Revenue